ArticleScience advances2020
On the design of precision nanomedicines.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Directing Assembly of Mesoscale Multi-Shell Morphologies of DNA Origami Crystals.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- The Reality of Active Targeting in Nanomedicine: Promise Versus Performance.Chembiochem : a European journal of chemical biology · 2026Review
- Choroid plexus remodeling linked to impaired CSF-mediated clearance and Alzheimer's disease progression.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Decoding the Conformation of Polylactic Acid in Block Copolymer Micelles.Journal of the American Chemical Society · 2026Article
- Targeting Inflammation-Oxidative Stress Crosstalk: Advances and Challenges in Nanocarrier-Based Interventional Strategies for Pulmonary Arterial Hypertension.International journal of nanomedicine · 2026Review
- Rapid amyloid-β clearance and cognitive recovery through multivalent modulation of blood-brain barrier transport.Signal transduction and targeted therapy · 2025Article
- Exosomes in cancer nanomedicine: biotechnological advancements and innovations.Molecular cancer · 2025Review
- Thermoplasmonic Polymersome Membranes byACS nano · 2025Article
- Receptor clustering tunes and sharpens the selectivity of multivalent binding.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- TRAIL as a Warrior in Nano-Sized Trojan Horse: Anticancer and Anti-Metastatic Effects of Nano-Formulations of TRAIL in Cell Culture and Animal Model Studies.Medicina (Kaunas, Lithuania) · 2024Review
- Amyloid-β in Alzheimer's disease: Structure, toxicity, distribution, treatment, and prospects.Ibrain · 2024Review
- The multivalency game ruling the biology of immunity.Biophysics reviews · 2023Review
- Determinants of Superselectivity─Practical Concepts for Application in Biology and Medicine.Accounts of chemical research · 2023Article
- Simple Complexity: Incorporating Bioinspired Delivery Machinery within Self-Assembled Peptide Biogels.Gels (Basel, Switzerland) · 2023Review
- Bimodal brush-functionalized nanoparticles selective to receptor surface density.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Multivalent Pattern Recognition through Control of Nano-Spacing in Low-Valency Super-Selective Materials.Journal of the American Chemical Society · 2022Article
- The Role of Host Cell Glycans on Virus Infectivity: The SARS-CoV-2 Case.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- A Multiscale Study of Phosphorylcholine Driven Cellular Phenotypic Targeting.ACS central science · 2022Article
- The interactions between DNA nanostructures and cells: A critical overview from a cell biology perspective.Acta biomaterialia · 2022Review
- The landscape of receptor-mediated precision cancer combination therapy via a single-cell perspective.Nature communications · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tight control on the selectivity of nanoparticles' interaction with biological systems is paramount for the development of targeted therapies. However, the large number of tunable parameters makes it difficult to identify optimal design "sweet spots" without guiding principles. Here, we combine superselectivity theory with soft matter physics into a unified theoretical framework and we prove its validity using blood brain barrier cells as target. We apply our approach to polymersomes functionalized with targeting ligands to identify the most selective combination of parameters in terms of particle size, brush length and density, as well as tether length, affinity, and ligand number. We show that the combination of multivalent interactions into multiplexed systems enable interaction as a function of the cell phenotype, that is, which receptors are expressed. We thus propose the design of a "bar-coding" targeting approach that can be tailor-made to unique cell populations enabling personalized therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.